Wednesday, June 10, 2015 Daily Archives

Goodwin Biotechnology and Aspyrian Therapeutics Collaborate on the Successful GMP Manufacturing and IND Submission for a Novel Antibody Drug Conjugate (ADC) Platform

Goodwin Biotechnology, Inc., a biological contract development and manufacturing organization (CDMO) that specializes in bioprocess development and GMP manufacturing of biopharmaceuticals utilizing mammalian cell culture expression systems and bioconjugation technologies, has partnered with Aspyrian Therapeutics to successfully complete process development, scale-up, and cGMP manufacturing of their novel antibody drug conjugate (ADC). Based on achieving this critical milestone, Aspyrian Therapeutics recently submitted and has received FDA’s acceptance of an Investigational New Drug (IND) Application for RM-1929, their first-in-class, precision targeted therapy…

Vetter Development Service Chicago Completes Recent On-Site Expansion Activities

Vetter, a leading contract development and manufacturing organization (CDMO) that specializes in aseptic filling, has announced today that a number of activities undertaken at its Skokie facility to satisfy existing and ever-increasing future customer demands have been completed. The initiatives include an additional staff shift for daily clinical manufacturing operations, as well as the doubling of capacities for performing visual inspection and in-process control (IPC). The facility also expanded its on-site offerings by giving customers the option to obtain secondary…